C.M. Bidwell & Associates’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

C.M. Bidwell & Associates’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-75	Closed	-$1K	–	544
2020 Q3	$1K	Buy	+75	New	+$793	﹤0.01%	445
2018 Q3	–	Sell	-15,150	Closed	-$368K	–	455
2018 Q2	$368K	Buy	+15,150	New	+$309K	0.34%	82
2016 Q4	–	Sell	-42,345	Closed	-$1.95M	–	305
2016 Q3	$1.95M	Buy	+42,345	New	+$2.21M	0.46%	83
2015 Q3	–	Sell	-6,095	Closed	-$360K	–	278
2015 Q2	$360K	Buy	6,095 +30	+0.5%	+$1.85K	0.08%	122
2015 Q1	$378K	Sell	6,065 -9,710	-62%	-$565K	0.08%	107
2014 Q4	$907K	Buy	15,775 +5,005	+46%	+$279K	0.21%	85
2014 Q3	$579K	Buy	10,770 +4,645	+76%	+$246K	0.14%	96
2014 Q2	$321K	Buy	+6,125	New	+$313K	0.07%	114

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

C.M. Bidwell & Associates's TEVA Position: Q4 2020 in Review

C.M. Bidwell & Associates sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q4 2020, closing a stake of 75 shares — an estimated $1K sold.

C.M. Bidwell & Associates first reported a position in TEVA in Q2 2014 and held it in 8 quarters. The position peaked at $1.95M in Q3 2016. 450 funds tracked by Wall St. Rank hold TEVA as of Q4 2020.

C.M. Bidwell & Associates reported no remaining Teva Pharmaceutical Industries Limited position as of Q4 2020 after selling out during the quarter.
C.M. Bidwell & Associates sold 75 Teva Pharmaceutical Industries Limited shares in Q4 2020, an estimated $1K.
C.M. Bidwell & Associates first reported a position in Teva Pharmaceutical Industries Limited in Q2 2014 and held it in 8 quarters.
C.M. Bidwell & Associates's Teva Pharmaceutical Industries Limited position peaked at $1.95M in Q3 2016.
450 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q4 2020.

Based on C.M. Bidwell & Associates's 13F filing for Q4 2020, filed 16 Feb 2021.